{"database": "lobbying", "table": "lobbying_activities", "rows": [[1189598, "b476da5c-8124-4f0f-a39a-88b89b940420", "Q4", "APOTEX CORP.", 310973, "APOTEX CORP.", 2011, "fourth_quarter", "PHA", "S. 27, the Preserve Access to Affordable Pharmaceuticals Act\nS. 1882, the FAIR Generics Act\nS. 296, HR 2245, The Preserving Access to Life Savings Medications Act Amending Section 505(j) of the Food, Drug, and Cosmetic Act, concerning the ability of generic pharmaceutical manufacturers to file counterclams seeking the correction of incorrect information submitted to FDA's Orange Book by patent owners or holders of New Drug Applications\n\nSupreme Court consideration of Novo Nordisk A/S and Novo Nordisk Inc. vs Caraco Pharmaceutical Laboratories Ltd. and Sub Pharmaceuticals Industries, Ltd.\n\nProspective action on legislation establishing a generic drug user fee program\n\nProspective action on legislation establishing a biosimilar user fee program\n\nEstablishment of a federal track and trace system for pharmaceuticals\n\nImportation of prescription narcotic products into the United States\n\nThe use of Risk Evaluation Mitigation Strategies (REMS) programs by brand drug companies to delay generic competition", "Federal Trade Commission (FTC),HOUSE OF REPRESENTATIVES,SENATE", null, 110000, 0, 0, "2012-01-18T09:54:02-05:00"]], "columns": ["id", "filing_uuid", "filing_type", "registrant_name", "registrant_id", "client_name", "filing_year", "filing_period", "issue_code", "specific_issues", "government_entities", "income_amount", "expense_amount", "is_no_activity", "is_termination", "received_date"], "primary_keys": ["id"], "primary_key_values": ["1189598"], "units": {}, "query_ms": 0.3402531147003174, "source": "Federal Register API & Regulations.gov API", "source_url": "https://www.federalregister.gov/developers/api/v1", "license": "Public Domain (U.S. Government data)", "license_url": "https://www.regulations.gov/faq"}